Upon the combined treatment of docetaxel and ADT, prostate cancer cells can recruit and induce the polarization of the tumor-associated macrophages to release CXCL12, which in turn promotes the survival of cancer cells via CXCR4 and mediate the drug resistance. This evidence concerns the gene CXCR4 and prostate carcinoma.